Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

27.93 -5.59 (-16.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗
Via Chartmill
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q4 2025 Results, Beats on EPS ↗
Via Chartmill
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗
Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for... 
Via MarketBeat
News headline image
Legend Biotech Announces Presentations at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗
Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech Q1 Earnings Call Highlights ↗
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of... 
Via MarketBeat
Topics Earnings
News headline image
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗
Yum China operates thousands of quick-service and casual dining restaurants across China under well-known international brands. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗
Futu Holdings delivers digital brokerage and wealth management services to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
News headline image
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Why Legend Biotech Stock Crushed the Market on Monday ↗
Two analysts weighed in positively about the company's future. 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q2 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
Legend Biotech (LEGN) Q4 2024 Earnings Transcript 
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗
Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.